Ann: Appendix 4E & 2020 Full Year Statutory Accounts, page-10

Hear what you are saying Tuts

But lest not forget that had it not been for Marc none of us would be discussing Lag-3, efti et al.

When Cvac - Prima Biomed's one trick that failed in P2 trials, he negotiated a buyout of Immutep for a relative 'song' backed by Lucy, the board and shareholders.

Look where we are now - multiple drug candidates in late stage trials with 4 of top 10 big pharma's. Cashed up too.

Marcs faux pas was being over enthusiastic pre AIPAC results - which were OK just not great - yet. As a micro cap biotech you don't get many chances to prove a drug successful and yet big pharma has many chances to fail and does often even at phase 3 level.

If and hopefully when efti is proven successful, Marc's salary and bonuses will pale into insignificance compared to the multiple increase in today's market cap - which may not be far away.

So - big shout out for Marc from me.
Bring it home son!!!!